Predictmedix AI Achieves Significant Milestones in Mental Health Detection and Analysis

Toronto, Ontario – December 5th, 2023 – Predictmedix AI Inc. (CSE: PMED) (OTCQB: PMEDF) (FRA:3QP) (the "Company" or "Predictmedix"), a leading provider of rapid health screening solutions powered by proprietary artificial intelligence (AI) is proud to announce ground-breaking achievements in the realm of mental health detection and analysis. With a commitment to advancing healthcare through innovative AI solutions, Predictmedix AI has successfully developed functionalities to detect depression, anxiety, and analyze individual mood and emotions.

Statistics from Forbes Health[1] reveal a staggering reality: an estimated 5% of adults worldwide grapple with depression, a figure potentially overshadowed by underreporting and undiagnosed cases, suggesting an even more pervasive mental health crisis. These alarming statistics underscore the critical need for proactive measures to address mental health challenges. In response, Predictmedix AI's cutting-edge technologies aim to revolutionize mental health care. The focus on early detection and nuanced analysis stands as a beacon of hope in the face of this escalating global mental health landscape. By harnessing the power of AI, Predictmedix AI aspires not just to identify but to intervene early, potentially reshaping outcomes and offering support to those silently battling mental health issues.

Key Accomplishments:

- **Depression and Anxiety Detection:** Predictmedix AI has developed advanced functionality to detect signs of depression and anxiety through its state-of-the-art AI algorithms. This remarkable capability addresses the critical need for early identification and intervention in mental health.
- **Mood and Emotion Analysis:** The company has successfully implemented functionalities to detect and analyze individual mood and emotions. This technology offers a comprehensive understanding of an individual's mental well-being, going beyond traditional diagnostics.

- **Significant Scan Milestone:** Predictmedix AI proudly announces the completion of over 250,000 individual scans. This milestone underscores the effectiveness and reliability of the AI-powered Safe Entry Station technology. Machine learning accuracy continues to improve across healthcare and other industries, positioning Predictmedix AI as a leader in the evolving landscape of health and safety applications.

"Our achievements in developing advanced functionalities for depression and anxiety detection, coupled with mood and emotion analysis, mark a significant step forward in leveraging AI for mental health. The culmination of over 250,000 individual scans is a testament to the real-world impact of our technology. This milestone isn't merely a numerical achievement; it echoes the lives touched and the potential for early interventions that can reshape the course of mental health outcomes. As machine learning accuracy continues to improve, we are dedicated to advancing innovation in health and safety applications for the benefit of individuals and communities," commented Dr. Rahul Kushwah, Chief Operating Officer of Predictmedix AI.

To receive company news, please sign up for alerts at the bottom of the page link below: https://predictmedix.com/press-releases/

[1]https://www.forbes.com/health/mind/depression-statistics/

About Predictmedix AI Inc.

Predictmedix AI Inc. (CSE: PMED) (OTCQB: PMEDF) (FRA:3QP) is an emerging provider of rapid health screening and remote patient care solutions globally. The Company's Safe Entry Stations – powered by a proprietary artificial intelligence (AI) – use multispectral cameras to analyze physiological data patterns and predict a variety of health issues including 19 physiological vital parameters, impairment by drugs or alcohol, fatigue, or various mental illnesses. Predictmedix AI's proprietary remote patient care platform empowers medical professionals with a suite of AI-powered tools to improve patient health outcomes. To learn more, please visit our website at www.Predictmedix.com or follow us on Twitter, Instagram or LinkedIn.

Public Relations Contact

For further media information or to set up an interview, please contact:

Nelson Hudes

Communications International (905) 660 9155

Nelson@hudescommunications.com

Dr. Rahul Kushwah (647) 889 6916

Caution Regarding Forward-Looking Information:

This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results of the Company. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances. The Company's securities have not been registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or applicable state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the United States or "U.S. Persons", as such term is defined in Regulations under the U.S. Securities Act, absent registration or an applicable exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful. Additionally, there are known and unknown risk factors which could cause the Company's actual results, performance or achievements to be materially different from any Page 4 of 4 future results, performance or achievements expressed or implied by the forward-looking information contained herein, such as, but not limited to dependence on obtaining regulatory approvals; the ability to obtain intellectual property rights related to its technology; limited operating history; general business, economic, competitive, political, regulatory and social uncertainties, and in particular, uncertainties related to COVID-19; risks related to factors beyond the control of the Company, including risks related to COVID-19; risks related to the Company's shares, including price volatility due to events that may or may not be within such party's control; reliance on management; and the emergency of additional competitors in the industry.

All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except required by law.

Disclaimer: "The Company is not making any express or implied claims that its product has the ability to diagnose, eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus) at this time.

THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED NOR DOES IT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.